Filtered By:
Source: Frontiers in Oncology
This page shows you your search results in order of date.
Order by Relevance | Date
Total 126 results found since Jan 2013.
GLS as a diagnostic biomarker in breast cancer: in-silico, in-situ, and in-vitro insights
ConclusionWe highlighted that GLS expression might be applicable as a diagnostic biomarker in breast cancer and possess significant implications in the growth and metastasis of tumor and the immune tumor microenvironment, sharing new insights into ontological and personalized medicine.
Source: Frontiers in Oncology - August 18, 2023 Category: Cancer & Oncology Source Type: research
UCA1 executes an oncogenic role in pancreatic cancer by regulating miR-582-5p/BRCC3
ConclusionUCA1 acted as an oncogene in pancreatic cancer by partly regulating miR-582-5p/BRCC3, which could be a new therapeutic target for pancreatic cancer.
Source: Frontiers in Oncology - July 25, 2023 Category: Cancer & Oncology Source Type: research
Anti-HPV16 oncoproteins siRNA therapy for cervical cancer using a novel transdermal peptide PKU12
In conclusion, the transdermal peptide PKU12 is potentially a good candidate for a siRNA delivery vehicle for the treatment of cervical cancer.
Source: Frontiers in Oncology - June 7, 2023 Category: Cancer & Oncology Source Type: research
Indolyl-chalcone derivatives trigger apoptosis in cisplatin-resistant mesothelioma cells through aberrant tubulin polymerization and deregulation of microtubule-associated proteins
DiscussionCIT-026 and CIT-223 are highly effective inducers of tumor cell apoptosis by disrupting microtubule assembly, with only modest effects on non-malignant cells. CITs are potent anti-tumor agents against MPM cells, in particular cells resistant to standard therapeutics, and thus warrant further evaluation as potential small-molecule therapeutics in MPM.
Source: Frontiers in Oncology - May 25, 2023 Category: Cancer & Oncology Source Type: research
SIRT1 mediated gastric cancer progression under glucose deprivation through the FoxO1-Rab7-autophagy axis
ConclusionThe SIRT1-FoxO1-Rab7 pathway is crucial for the autophagy and malignant biological behaviors of GC cells under GD conditions, which could be a new target for the treatment of GC.
Source: Frontiers in Oncology - May 24, 2023 Category: Cancer & Oncology Source Type: research
Vitamin D inhibits osteosarcoma by reprogramming nonsense-mediated RNA decay and SNAI2-mediated epithelial-to-mesenchymal transition
In this study, we assessed the impact of vitamin D and its receptor (VDR) on NMD-ROS-EMT signaling in in vitro and in vivo osteosarcoma animal models. Initiation of VDR signaling facilitated the enrichment of EMT pathway genes, after which 1,25(OH)2D, the active vitamin D derivative, inhibited the EMT pathway in osteosarcoma subtypes. The ligand-bound VDR directly downregulated the EMT inducer SNAI2, differentiating highly metastatic from low metastatic subtypes and 1,25(OH)2D sensitivity. Moreover, epigenome-wide motif and putative target gene analysis revealed the VDR’s integration with NMD tumorigenic and immunogenic ...
Source: Frontiers in Oncology - May 9, 2023 Category: Cancer & Oncology Source Type: research
Near-infrared fluorescence imaging of hepatocellular carcinoma cells regulated by β-catenin signaling pathway
ConclusionsOur study uncovers a mechanism that links the distribution and expression of the membrane transporters OATP2B1 and ABCG2 to the tumor-specific accumulation of MHI-148, and provides evidence supporting a regulating role of the β-catenin signaling pathway in OATP2B1 and ABCG2- induced retention of MHI-148 inHCC tissues, and strategy targeting key components of MHI-148 transport machinery may be a potential approach to improve HCC imaging.
Source: Frontiers in Oncology - March 29, 2023 Category: Cancer & Oncology Source Type: research
UCHL3 promotes hepatocellular carcinoma cell migration by de-ubiquitinating and stabilizing Vimentin
ConclusionUCHL3 was highly expressed in HCC and functioned as an oncogene. Vimentin is a novel substrate of UCHL3 and its stabilization and de-ubiquitination enhanced HCC cell migration.
Source: Frontiers in Oncology - March 9, 2023 Category: Cancer & Oncology Source Type: research
RNF6 activates TGF- β1/c-Myb pathway to promote EMT in esophageal squamous cell carcinoma
ConclusionRNF6 promotes the proliferation, invasion, and migration of ESCC cells possibly by activating the TGF-β1/c-Myb pathway and affects the progression of ESCC.
Source: Frontiers in Oncology - February 9, 2023 Category: Cancer & Oncology Source Type: research
Synergistic treatment of osteosarcoma with biomimetic nanoparticles transporting doxorubicin and siRNA
ConclusionDOX/siSUR-PLGA@MSCM NPs can show improved therapeutic effects in osteosarcoma patients due to the combination of a chemotherapeutic drug and gene therapy based on their good tumor targeting and biosafety.
Source: Frontiers in Oncology - January 23, 2023 Category: Cancer & Oncology Source Type: research
siAKR1C3@PPA complex nucleic acid nanoparticles inhibit castration-resistant prostate cancer in vitro
ConclusionWe concluded that siAKR1C3@PPA may arrest the cell cycle and affect cell proliferation.
Source: Frontiers in Oncology - December 16, 2022 Category: Cancer & Oncology Source Type: research
JNK inhibitor IX restrains pancreatic cancer through p53 and p21
This study underlines the need for modeling systems in testing therapeutic options as JNK2 was previously not indicated as a potential target.
Source: Frontiers in Oncology - December 7, 2022 Category: Cancer & Oncology Source Type: research
BPTF promotes the progression of distinct subtypes of breast cancer and is a therapeutic target
ConclusionThese studies demonstrate BPTF activation in distinct breast cancer subtypes, identify pathways by which BPTF promotes breast cancer progression, and suggest BPTF as a rational target for breast cancer therapy.
Source: Frontiers in Oncology - November 30, 2022 Category: Cancer & Oncology Source Type: research
High expression of RARG accelerates ovarian cancer progression by regulating cell proliferation
ConclusionsHigh expression of RARG could promote OC cell proliferation and was an independent predictor of poor prognosis. RARG might work as a potential molecular target and biomarker for individualized diagnosis and treatment in OC patients.
Source: Frontiers in Oncology - November 29, 2022 Category: Cancer & Oncology Source Type: research
HLA-BAT1 alters migration, invasion and pro-inflammatory cytokines in prostate cancer
The objective of this study is to understand the role of BAT1 in prostate cancer. In vitro studies showed that BAT1 down-regulation increased cell migration and invasion. In contrast, BAT1 overexpression decreased cell migration and invasion. RT-PCR analysis showed differential expression of pro-inflammatory cytokines (TNF-α and IL-6) and cell adhesion and migration genes (MMP10, MMP13, and TIMPs) in BAT1 overexpressed cells when compared to BAT1 siRNA cells. Our in vivo studies demonstrated up-regulation of TNF-α, IL-6, and MMP10 in tumors developed from transfected BAT1 shRNA cells when compared to tumors developed fro...
Source: Frontiers in Oncology - November 23, 2022 Category: Cancer & Oncology Source Type: research
